SEC Tracker
Get the app

Cellectar Biosciences CLRB

Cellectar Biosciences reported a net loss of $7.98 million

Cellectar Biosciences (CLRB) filed a 10-Q with the SEC on Nov 10, 2026, 6:56 am ET. Source: the filing on SEC EDGAR.

Quarterly report, 3 new risk factors

Form
10-Q
Filed
Importance
Major
  1. Net loss: $7.98 million for the three months ended Sep 30, 2026
  2. Diluted EPS: -$0.46 for the three months ended Sep 30, 2026
  3. Cash and equivalents: $24.58 million at Sep 30, 2026

Written from the 10-Q on EDGAR. AI can make mistakes. Check the filing.

Get the appView on EDGAR

Going-concern warning repeated

“These uncertainties raise substantial doubt about the Company's ability to continue as a going concern.”
In the notes to the financial statements. Read it in the filing 10-Q on EDGAR

Also in the prior 10-Q (filed Aug 13, 2026). Prior report Prior on EDGAR

Quoted from the filing.

Get an email when Cellectar Biosciences files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

What changed since last quarter

3 new risk factors · 1 new legal mention

Compared with the 10-Q for the period ended Jun 30, 2026.

Key numbers from the XBRL in this filing and the previous one.
This filingPreviousChange vs prior 10-Q
Operating income and margin−$8.1M−$7.2M−13%
Net income−$7.98M−$6.93M−15%
Operating cash flow−$9.41M−$6.01M−57%
Cash$24.58M$33.99M−28%
New risk factors (3)
  • In addition to the other information set forth in this report, you should carefully review and consider the information regarding certain risks and uncertainties facing the Company that could have a material adverse effect on our business prospects, financial condition, results of operations, liquidity and available…
  • Although we received net proceeds of approximately $31.7 million from our May 2026 financing and have initiated activities relating to our Phase 3 confirmatory trial, our existing cash and cash equivalents are not sufficient to complete the Phase 3 confirmatory trial or otherwise to fully execute our regulatory…
  • We may not receive any proceeds from the milestone-based warrants issued in our May 2026 financing, and the exercise of those warrants would substantially dilute our stockholders. +1 more paragraph
New legal mentions (1)
  • An independent Data Monitoring Committee (iDMC) did not identify dose-limiting toxicities in any cohort.

Data on this page was fetched . The filing on SEC.gov is the record.